Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1927)	11/2/2000 10:06:40 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 52153

<or sickle cell> Anybody happen to have bottomfished Supergen?

To: Biomaven who wrote (1927)	11/3/2000 10:51:06 AM
From: BulbaMan	Read Replies (1) \| Respond to of 52153

Peter: You may be correct, but the key event energizing the Biotech Boom last fall was the announcement that Chromosome 22 was sequenced. So, maybe the Big Biotech Event doesn't need to be so Big. It could well be, for example, that an announcement by a big HMO that they've begun genetic testing for drug responses (the $50 test mentioned in the Fortune piece) would really catch the media's and investing public's attention. By the way, PPGx, (the company mentioned in Fortune) is private but its majority owner, AXPH, is publicly traded and seems undervalued to me.